Intravenous cyclosporine and tacrolimus caused anaphylaxis but oral cyclosporine capsules were tolerated in an allogeneic bone marrow transplant recipient.
A Japanese female patient with angioimmunoblastic T cell lymphoma underwent allogeneic bone marrow transplantation (BMT) from her brother. Cyclosporine at a dose of 3 mg/kg was started by continuous infusion over 24 h on day -1 of BMT. Within a couple of minutes after the infusion was begun, she developed diffuse pruritic erythema on her whole body and tachycardia. The infusion was immediately stopped and corticosteroid was given, resulting in disappearance of the erythema gradually. She was then switched to intravenous tacrolimus. However, she suffered urticalial erythema again. Since polyoxyethylated castor oil, a solubilizer used in the injective formulation of both cyclosporine and tacrolimus, is considered to be responsible for the reaction, she was given oral capsules of cyclosporine (Sandimmun) in which polyoxyethylated castor oil was not contained. No further anaphylactic reaction was observed. The BM cells were successfully engrafted without causing severe GVHD. She was discharged on cyclosporine capsules without any further adverse effects. Anaphylaxis to intravenous cyclosporine and tacrolimus is a very rare but a serious complication. Our present case indicates that oral capsule of Sandimmun is a safe alternative to prevent GVHD in such a case of anaphylactic reaction against intravenous formulation.
Takamatsu
Y
Y
First Department of Internal Medicine, Fukuoka University School of Medicine, Fukuoka, Japan.
Ishizu
M
M
Ichinose
I
I
Ogata
K
K
Onoue
M
M
Kumagawa
M
M
Suzumiya
J
J
Tamura
K
K
D000284:Administration, Oral; D000707:Anaphylaxis / Q000139:chemically induced*; D016026:Bone Marrow Transplantation; D002214:Capsules; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy / Q000628:therapy; D007262:Infusions, Intravenous; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D014184:Transplantation, Homologous
D002214:Capsules; D016572:Cyclosporine; D016559:Tacrolimus